A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome

Zeeshan Javed, Maria Papageorgiou, Harshal Deshmukh, Eric S Kilpatrick, Vincent Mann, Lynsey Corless, George Abouda, Alan S Rigby, Stephen L Atkin, Thozhukat Sathyapalan, Zeeshan Javed, Maria Papageorgiou, Harshal Deshmukh, Eric S Kilpatrick, Vincent Mann, Lynsey Corless, George Abouda, Alan S Rigby, Stephen L Atkin, Thozhukat Sathyapalan

Abstract

Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemistry in patients with NAFLD; however, its effects on PCOS are unknown. This randomized, double-blind, placebo-controlled study explored the effect of vitamin D supplementation on cardiovascular risk factors (high-sensitivity C-reactive protein (hs-CRP), weight, body mass index (BMI), lipid profile, glucose levels, insulin levels, the homeostatic model assessment-insulin resistance (HOMA-IR), hormones (free androgen index (FAI), testosterone, sex hormone binding globulin (SHBG), and liver markers (alanine aminotransferase (ALT), hyaluronic acid (HA), N-terminal pro-peptide of type III procollagen (PIIINP), tissue inhibitor of metallo-proteinases-1 (TIMP-1), and the enhanced liver fibrosis (ELF) score). Forty women with PCOS were recruited and randomized to vitamin D (3200 IU) or placebo daily for 3 months. All outcomes were measured at baseline and 3 months follow-up (FU). Greater increases in vitamin D levels were shown in the supplementation group (vitamin D, baseline: 25.6 ± 11.4 nmol/L, FU: 90.4 ± 19.5 nmol/L vs. placebo, baseline: 30.9 ± 11.1 nmol/L, FU: 47.6 ± 20.5 nmol/L, p < 0.001). Between groups comparisons (% baseline change) revealed significant differences in ALT (p = 0.042) and a weak effect indicating a greater reduction in the HOMA-IR in the vitamin D group (p = 0.051). No further between group differences were seen in other cardiovascular risk factor, liver markers, or hormones. This study supports beneficial effects of vitamin D supplementation on liver markers and modest improvements in insulin sensitivity in vitamin D deficient women with PCOS.

Keywords: cardiovascular risk factors; hormones; liver markers; polycystic ovary syndrome; vitamin D.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart showing the progress of patients throughout the trial.

References

    1. Azziz R. Polycystic Ovary Syndrome. Obstet. Gynecol. 2018;132:321–336. doi: 10.1097/AOG.0000000000002698.
    1. Wild R.A., Carmina E., Diamanti-Kandarakis E., Dokras A., Escobar-Morreale H.F., Futterweit W., Lobo R., Norman R.J., Talbott E., Dumesic D.A. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 2010;95:2038–2049. doi: 10.1210/jc.2009-2724.
    1. Cai J., Wu C.H., Zhang Y., Wang Y.Y., Xu W.D., Lin T.C., Li S.X., Wang L.H., Zheng J., Sun Y., et al. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance. Int. J. Obes. (Lond.) 2017;41:1341–1347. doi: 10.1038/ijo.2017.116.
    1. Macut D., Tziomalos K., Bozic-Antic I., Bjekic-Macut J., Katsikis I., Papadakis E., Andric Z., Panidis D. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum. Reprod. 2016;31:1347–1353. doi: 10.1093/humrep/dew076.
    1. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012;107:811–826. doi: 10.1038/ajg.2012.128.
    1. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010;363:1341–1350. doi: 10.1056/NEJMra0912063.
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121–1140. doi: 10.1007/s00125-016-3902-y.
    1. He C.L., Lin Z.M., Robb S.W., Ezeamama A.E. Serum vitamin D levels and polycystic ovary syndrome: A systematic review and meta-analysis. Nutrients. 2015;7:4555–4577. doi: 10.3390/nu7064555.
    1. Muscogiuri G., Policola C., Prioletta A., Sorice G., Mezza T., Lassandro A., Della Casa S., Pontecorvi A., Giaccari A. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clin. Nutr. 2012;31:476–480. doi: 10.1016/j.clnu.2011.12.010.
    1. Abootorabi M.S., Ayremlou P., Behroozi-Lak T. The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: A randomized placebo-controlled trial. Gynecol. Endocrinol. 2018;34:489–494. doi: 10.1080/09513590.2017.1418311.
    1. Lagowska K., Bajerska J., Jamka M. The role of vitamin d oral supplementation in insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2018;10:1637. doi: 10.3390/nu10111637.
    1. Wehr E., Pieber T.R., Obermayer-Pietsch B. Effect of vitamin d3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: A pilot study. J. Endocrinol. Investig. 2011;34:757–763.
    1. Irani M., Seifer D.B., Grazi R.V., Julka N., Bhatt D., Kalgi B., Irani S., Tal O., Lambert-Messerlian G., Tal R. Vitamin D supplementation decreases TGF-β1 bioavailability in pcos: A randomized placebo-controlled trial. J. Clin. Endocrinol. Metab. 2015;100:4307–4314. doi: 10.1210/jc.2015-2580.
    1. Pal L., Berry A., Coraluzzi L., Kustan E., Danton C., Shaw J., Taylor H. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol. Endocrinol. 2012;28:965–968. doi: 10.3109/09513590.2012.696753.
    1. Jamilian M., Foroozanfard F., Rahmani E., Talebi M., Bahmani F., Asemi Z. Effect of two different doses of vitamin d supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients. 2017;9:1280. doi: 10.3390/nu9121280.
    1. Rahimi-Ardabili H., Pourghassem Gargari B., Farzadi L. Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. J. Endocrinol. Investig. 2013;36:28–32.
    1. Raja-Khan N., Shah J., Stetter C.M., Lott M.E., Kunselman A.R., Dodson W.C., Legro R.S. High-dosevitaminD supplementation and measures of insulin sensitivity in polycystic ovary syndrome: A randomized, controlled pilot trial. Fertil. Steril. 2014;101:1740–1746. doi: 10.1016/j.fertnstert.2014.02.021.
    1. Garg G., Kachhawa G., Ramot R., Khadgawat R., Tandon N., Sreenivas V., Kriplani A., Gupta N. Effect of vitamin D supplementation on insulin kinetics and cardiovascular risk factors in polycystic ovarian syndrome: A pilot study. Endocr. Connect. 2015;4:108–116. doi: 10.1530/EC-15-0001.
    1. Trummer C., Schwetz V., Kollmann M., Wolfler M., Munzker J., Pieber T.R., Pilz S., Heijboer A.C., Obermayer-Pietsch B., Lerchbaum E. Effects of vitamin D supplementation on metabolic and endocrine parameters in pcos: A randomized-controlled trial. Eur. J. Nutr. 2018 doi: 10.1007/s00394-018-1760-8.
    1. Asemi Z., Foroozanfard F., Hashemi T., Bahmani F., Jamilian M., Esmaillzadeh A. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clin. Nutr. 2015;34:586–592. doi: 10.1016/j.clnu.2014.09.015.
    1. Eliades M., Spyrou E. Vitamin D: A new player in non-alcoholic fatty liver disease? World J. Gastroenterol. 2015;21:1718–1727. doi: 10.3748/wjg.v21.i6.1718.
    1. Cicero A.F.G., Colletti A. An update on the safety of nutraceuticals and effects on lipid parameters. Expert Opin. Drug Saf. 2018;17:303–313. doi: 10.1080/14740338.2018.1429404.
    1. Papapostoli I., Lammert F., Stokes C.S. Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP) J. Gastrointest. Liver Dis. 2016;25:175–181.
    1. Lorvand Amiri H., Agah S., Mousavi S.N., Hosseini A.F., Shidfar F. Regression of non-alcoholic fatty liver by vitamin d supplement: A double-blind randomized controlled clinical trial. Arch. Iran. Med. 2016;19:631–638.
    1. Geier A., Eichinger M., Stirnimann G., Semela D., Tay F., Seifert B., Tschopp O., Bantel H., Jahn D., Marques Maggio E., et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: A double-blinded, randomized, placebo-controlled pilot study. Scand. J. Gastroenterol. 2018;53:1114–1120. doi: 10.1080/00365521.2018.1501091.
    1. European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 2015;63:237–264. doi: 10.1016/j.jhep.2015.04.006.
    1. Lichtinghagen R., Pietsch D., Bantel H., Manns M.P., Brand K., Bahr M.J. The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. J. Hepatol. 2013;59:236–242. doi: 10.1016/j.jhep.2013.03.016.
    1. Pinzani M. The ELF panel: A new crystal ball in hepatology? Gut. 2010;59:1165–1167. doi: 10.1136/gut.2010.214932.
    1. Parkes J., Roderick P., Harris S., Day C., Mutimer D., Collier J., Lombard M., Alexander G., Ramage J., Dusheiko G., et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59:1245–1251. doi: 10.1136/gut.2009.203166.
    1. Kim B.K., Kim H.S., Park J.Y., Kim D.Y., Ahn S.H., Chon C.Y., Park Y.N., Han K.H., Kim S.U. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS ONE. 2012;7:e41964. doi: 10.1371/journal.pone.0041964.
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum. Reprod. 2004;19:41–47. doi: 10.1093/humrep/deh098.
    1. Aspray T.J., Bowring C., Fraser W., Gittoes N., Javaid M.K., Macdonald H., Patel S., Selby P., Tanna N., Francis R.M. National Osteoporosis S: National Osteoporosis Society vitamin D guideline summary. Age Ageing. 2014;43:592–595. doi: 10.1093/ageing/afu093.
    1. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment—Insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Sathyapalan T., Shepherd J., Arnett C., Coady A.M., Kilpatrick E.S., Atkin S.L. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin. Chem. 2010;56:1696–1700. doi: 10.1373/clinchem.2010.144014.
    1. Nakano T., Cheng Y.F., Lai C.Y., Hsu L.W., Chang Y.C., Deng J.Y., Huang Y.Z., Honda H., Chen K.D., Wang C.C., et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J. Hepatol. 2011;55:415–425. doi: 10.1016/j.jhep.2010.11.028.
    1. Hochrath K., Stokes C.S., Geisel J., Pollheimer M.J., Fickert P., Dooley S., Lammert F. Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. Hepatol. Int. 2014;8:443–452. doi: 10.1007/s12072-014-9548-2.
    1. Sakpal M., Satsangi S., Mehta M., Duseja A., Bhadada S., Das A., Dhiman R.K., Chawla Y.K. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial. JGH Open. 2017;1:62–67. doi: 10.1002/jgh3.12010.
    1. Dasarathy J., Varghese R., Feldman A., Khiyami A., McCullough A.J., Dasarathy S. Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. J. Nutr. 2017;147:1938–1946. doi: 10.3945/jn.117.254292.
    1. Abramovitch S., Dahan-Bachar L., Sharvit E., Weisman Y., Ben Tov A., Brazowski E., Reif S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60:1728–1737. doi: 10.1136/gut.2010.234666.
    1. Potter J.J., Liu X., Koteish A., Mezey E. 1,25-dihydroxyvitamin D3 and its nuclear receptor repress human alpha1 (I) collagen expression and type I collagen formation. Liver Int. 2013;33:677–686. doi: 10.1111/liv.12122.
    1. Ding N., Yu R.T., Subramaniam N., Sherman M.H., Wilson C., Rao R., Leblanc M., Coulter S., He M., Scott C., et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601–613. doi: 10.1016/j.cell.2013.03.028.
    1. Li R., Guo E., Yang J., Li A., Yang Y., Liu S., Liu A., Jiang X. 1,25(OH)2 D3 attenuates hepatic steatosis by inducing autophagy in mice. Obesity. 2017;25:561–571. doi: 10.1002/oby.21757.
    1. Sharifi N., Amani R., Hajiani E., Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 2014;47:70–80. doi: 10.1007/s12020-014-0336-5.
    1. Foroughi M., Maghsoudi Z., Ghiasvand R., Iraj B., Askari G. Effect of vitamin D supplementation on c-reactive protein in patients with nonalcoholic fatty liver. Int. J. Prev. Med. 2014;5:969–975.
    1. Foroughi M., Maghsoudi Z., Askari G. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD) Iran J. Nurs. Midwifery Res. 2016;21:100–104.
    1. Pergialiotis V., Karampetsou N., Panagopoulos P., Trakakis E., Papantoniou N. The effect of Vitamin D supplementation on hormonal and glycaemic profile of patients with PCOS: A meta-analysis of randomised trials. Int. J. Clin. Pract. 2017;71 doi: 10.1111/ijcp.12957.
    1. Xue Y., Xu P., Xue K., Duan X., Cao J., Luan T., Li Q., Gu L. Effect of vitamin D on biochemical parameters in polycystic ovary syndrome women: A meta-analysis. Arch. Gynecol. Obstet. 2017;295:487–496. doi: 10.1007/s00404-016-4247-y.
    1. Said A., Akhter A. Meta-Analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann. Hepatol. 2017;16:538–547. doi: 10.5604/01.3001.0010.0284.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit